Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 714

Drug Profile

AMG 714

Alternative Names: HuMax anti-IL15; HuMax-IL-15; PRV-015

Latest Information Update: 14 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Developer Amgen; Celimmune
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coeliac disease
  • Discontinued Inflammation; Lymphoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 05 Nov 2018 Amgen and Provention Bio enters into a licensing and co-development agreement for AMG 714 for Coeliac disease
  • 05 Nov 2018 Provention Bio plans a phase IIb trial for Coeliac disease
  • 20 Feb 2018 Amgen initiates an expanded-access programme for Coeliac disease in February 2018 (NCT03439475)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top